JAZZ — Jazz Pharmaceuticals plc

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1232524 · Ireland
Last close
$240.71
Market Cap
$15.45B
52W High
$266.38
52W Low
$156.95
ADV30
807,025
Next earnings
2026-11-02

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 1,243,000,000 1,132,400,000 340,800,000 -483,400,000 11,997,700,000 2,036,400,000 7,805,900,000
Jun 2026 1,208,300,000 1,091,900,000 325,200,000 192,800,000 11,080,900,000 1,619,800,000 6,279,200,000
Mar 2026 1,068,900,000 934,800,000 336,600,000 293,100,000 11,859,600,000 1,844,300,000 7,327,300,000
Dec 2025 1,197,926,000 1,044,398,000 254,535,000 203,451,000 11,659,340,000 1,391,899,000 7,340,756,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$1,692,518,000
Investing CF
$-977,962,000
Financing CF
$-3,860,000
CapEx
$-278,429,000
Dividends Paid
—
Buybacks
$-225,000,000
EPS Diluted TTM
$2.94
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$423,600,000
Inventory
$454,000,000
Receivables
$873,700,000
ST Investments
$820,000,000
EBIT TTM
$427,677,000
Pretax Income TTM
$259,771,000
Interest Exp TTM
$167,906,000
Analysts
22

Yahoo Snapshot (yfinance, live)

Total Revenue
$4,718,185,984
EBITDA
$2,010,866,944
Free Cash Flow
$1,681,385,344
Enterprise Value
$17,857,622,016
Total Cash
$2,856,399,872
Total Debt
$5,645,000,192
Shares Out
64,189,052
Trailing EPS
$3.38
Book Value
$65.39
ROE
5.1%
ROA
6.9%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 4,267,586,000 517,622,000 -356,148,000 11,659,340,000 7,340,756,000 4,318,584,000 1,355,773,000
Dec 2024 4,068,950,000 726,630,000 560,120,000 12,012,257,000 7,918,501,000 4,093,756,000 1,395,908,000
Dec 2023 3,834,204,000 597,580,000 414,832,000 11,393,359,000 7,656,362,000 3,736,997,000 1,092,007,000
Dec 2022 3,659,374,000 512,268,000 -224,060,000 10,835,255,000 7,749,521,000 3,085,734,000 1,271,977,000

TTM Snapshot

Revenues TTM
$4,601,233,000
NetIncome TTM
$940,763,000
OpCashFlow TTM
—
Assets (Latest)
$11,080,900,000
Forward EPS
$25.99

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $170.00 · spot: $247.77 · call volume: 193 · put volume: 28
Expected Move to 2027-01-15: ±$23.60 (9.52%) — implied range $224.17 – $271.37 · ATM straddle on $250.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
BBIO BridgeBio Pharma, Inc. $14.96B $76.80 —
ASND Ascendis Pharma A/S $17.84B $271.19 —
ELAN Elanco Animal Health Inc $12.92B $25.85 —
RDY DR REDDYS LABORATORIES LTD $12.32B $14.79 —
ALNY ALNYLAM PHARMACEUTICALS, INC. $20.96B $156.50 —

News headlines (Yahoo Finance, 1h cache)

Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock
2026-11-09 13:15 · Yahoo
BRC Therapeutics Appoints Kimberly Spancake as Senior Director, Clinical
2026-11-05 17:12 · Yahoo
Jazz Pharmaceuticals (JAZZ) Stock Jumps On Q2 Earnings Turnaround
2026-11-03 22:20 · Yahoo
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-11-03 21:15 · Yahoo
Jazz Pharmaceuticals PLC (JAZZ) (Q3 2026) Earnings Call Highlights: Record $1. ...
2026-11-03 21:02 · Yahoo
Jazz Pharmaceuticals plc Q3 2026 Earnings Call Summary
2026-11-03 13:30 · Yahoo
Jazz: Q3 Earnings Snapshot
2026-11-03 04:29 · Yahoo
Jazz (JAZZ) Q3 2026 Earnings Call Transcript
2026-11-03 04:28 · Yahoo
Jazz Pharmaceuticals (JAZZ) Will Present Phase 3 And Phase 2 Brain Cancer Data
2026-11-03 03:21 · Yahoo
Jazz Pharmaceuticals (JAZZ) Could Be 27% Undervalued As Record Revenue Lifts Outlook
2026-11-03 02:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.